Global Irritable Bowel Syndrome (IBS) Diagnostics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Irritable Bowel Syndrome (IBS) Diagnostics market size will reach US$ million by 2031.
Irritable bowel syndrome (IBS) is defined as a gastro-intestinal disorder causing discomfort in the stomach, along with diarrhea, and constipation. IBS can develop after a severe session of diarrhea (gastroenteritis) caused by bacteria or a virus. IBS might also be associated with a surplus of bacteria in the bowels (bacterial overgrowth). People exposed to stressful events, especially in childhood, tend to have more symptoms of IBS. IBS diagnostics is done through medical history, physical exam, and imaging tests. However, IBS is majorly diagnosed by lactose intolerance tests, breath test for bacterial overgrowth, blood test, and stool test. The tests are done based on symptoms such as constipation-predominant, diarrhea-predominant, or mixed. It can also detect by various imaging tests such as CT Scan or X-ray, upper endoscopy, and colonoscopy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Irritable Bowel Syndrome (IBS) Diagnostics Industry Forecast” looks at past sales and reviews total world Irritable Bowel Syndrome (IBS) Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Irritable Bowel Syndrome (IBS) Diagnostics sales for 2025 through 2031. With Irritable Bowel Syndrome (IBS) Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Irritable Bowel Syndrome (IBS) Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Irritable Bowel Syndrome (IBS) Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Irritable Bowel Syndrome (IBS) Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Irritable Bowel Syndrome (IBS) Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Irritable Bowel Syndrome (IBS) Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Irritable Bowel Syndrome (IBS) Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome (IBS) Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Laboratory Tests
Imaging Tests
Segmentation by Application:
Hospitals and Clinics
Diagnostic Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Commonwealth Diagnostics International
Genova Diagnostics
Gemelli Biotech
Prometheus Laboratories
Inova Diagnostics, Inc.
Biohit Oyj
Aerodiagnostics, LLC.
Metabolic Solutions, Inc.
Sysmex Corporation
Buhlmann Laboratories AG
Please note: The report will take approximately 2 business days to prepare and deliver.
Irritable bowel syndrome (IBS) is defined as a gastro-intestinal disorder causing discomfort in the stomach, along with diarrhea, and constipation. IBS can develop after a severe session of diarrhea (gastroenteritis) caused by bacteria or a virus. IBS might also be associated with a surplus of bacteria in the bowels (bacterial overgrowth). People exposed to stressful events, especially in childhood, tend to have more symptoms of IBS. IBS diagnostics is done through medical history, physical exam, and imaging tests. However, IBS is majorly diagnosed by lactose intolerance tests, breath test for bacterial overgrowth, blood test, and stool test. The tests are done based on symptoms such as constipation-predominant, diarrhea-predominant, or mixed. It can also detect by various imaging tests such as CT Scan or X-ray, upper endoscopy, and colonoscopy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Irritable Bowel Syndrome (IBS) Diagnostics Industry Forecast” looks at past sales and reviews total world Irritable Bowel Syndrome (IBS) Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Irritable Bowel Syndrome (IBS) Diagnostics sales for 2025 through 2031. With Irritable Bowel Syndrome (IBS) Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Irritable Bowel Syndrome (IBS) Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Irritable Bowel Syndrome (IBS) Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Irritable Bowel Syndrome (IBS) Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Irritable Bowel Syndrome (IBS) Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Irritable Bowel Syndrome (IBS) Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Irritable Bowel Syndrome (IBS) Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome (IBS) Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Laboratory Tests
Imaging Tests
Segmentation by Application:
Hospitals and Clinics
Diagnostic Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Commonwealth Diagnostics International
Genova Diagnostics
Gemelli Biotech
Prometheus Laboratories
Inova Diagnostics, Inc.
Biohit Oyj
Aerodiagnostics, LLC.
Metabolic Solutions, Inc.
Sysmex Corporation
Buhlmann Laboratories AG
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
90 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Irritable Bowel Syndrome (IBS) Diagnostics Market Size by Player
- 4 Irritable Bowel Syndrome (IBS) Diagnostics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
